Skip to main content
Top
Published in: Rheumatology International 2/2011

01-02-2011 | Case Report

Intraarticular adalimumab in a patient with pigmented villonodular synovitis

Author: Senol Kobak

Published in: Rheumatology International | Issue 2/2011

Login to get access

Abstract

Pigmented villonodular synovitis is a chronic inflammatory disease progressing with histological villonodular hyperplasia in synovium, fibrosis and accumulation of hemosiderin. Knee joint is frequently involved leading to severe joint damage and disability in untreated cases. Treatment options include surgical intervention or radio-synovectomy with intraarticular yttrium-90. The case presented here includes significant clinical and radiological disease regression after intraarticular adalimumab in a patient diagnosed with radiologically and histologically confirmed pigmented villonodular synovitis who did not consent to surgical intervention.
Literature
1.
go back to reference Ofluoglu O (2006) Pigmented villonodular synovitis. Orthop Clin North Am 37:3–33CrossRef Ofluoglu O (2006) Pigmented villonodular synovitis. Orthop Clin North Am 37:3–33CrossRef
2.
go back to reference Byers PD, Cotton RE, Deacon OW, Lowy M, Newman PH, Sissons HA et al (1968) The diagnosis and treatment of pigmented villonodular synovitis. J Bone Jt Surg Br 50:290–305 Byers PD, Cotton RE, Deacon OW, Lowy M, Newman PH, Sissons HA et al (1968) The diagnosis and treatment of pigmented villonodular synovitis. J Bone Jt Surg Br 50:290–305
3.
go back to reference Akgun I, Ogut T, Kesmezacar H, Dervisoglu S (2003) Localized pigmented villonodular synovitis of the knee. Orthopedics 26:1131–1135PubMed Akgun I, Ogut T, Kesmezacar H, Dervisoglu S (2003) Localized pigmented villonodular synovitis of the knee. Orthopedics 26:1131–1135PubMed
4.
go back to reference Flandry F, Hughston JC, McCann SB, Kurtz DM (1994) Diagnostic features of diffuse pigmented villonodular synovitis of the knee. Clin Orthop Relat Res 298:212–220PubMed Flandry F, Hughston JC, McCann SB, Kurtz DM (1994) Diagnostic features of diffuse pigmented villonodular synovitis of the knee. Clin Orthop Relat Res 298:212–220PubMed
5.
go back to reference Jaffe HL, Lichtenstein L, Sutro CJ (1941) Pigmented villonodularis synovitis: bursitis and tenosynovitis. Arch Pathol 31:731–765 Jaffe HL, Lichtenstein L, Sutro CJ (1941) Pigmented villonodularis synovitis: bursitis and tenosynovitis. Arch Pathol 31:731–765
6.
go back to reference Aigner T, Oehler S, Niedobitek HG, Fassbender G, Kirchner T (1998) Iron deposits, cell populations and proliferative activity in pigmented villonodular synovitis of the knee joint. Verh Dtsch Ges Pathol 82:327–331PubMed Aigner T, Oehler S, Niedobitek HG, Fassbender G, Kirchner T (1998) Iron deposits, cell populations and proliferative activity in pigmented villonodular synovitis of the knee joint. Verh Dtsch Ges Pathol 82:327–331PubMed
7.
go back to reference Neale SD, Kristelly R, Gundle R, Quinn JM, Athanasou NA (1997) Giant cells in pigmented villonodular synovitis express an osteoclast phenotype. J Clin Pathol 50:605–608CrossRefPubMed Neale SD, Kristelly R, Gundle R, Quinn JM, Athanasou NA (1997) Giant cells in pigmented villonodular synovitis express an osteoclast phenotype. J Clin Pathol 50:605–608CrossRefPubMed
8.
go back to reference O’Keefe RJ, Rosier RN, Teot LA, Stewart JM, Hicks DG (1998) Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction. Iowa Orthop J 18:26–34PubMed O’Keefe RJ, Rosier RN, Teot LA, Stewart JM, Hicks DG (1998) Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction. Iowa Orthop J 18:26–34PubMed
9.
go back to reference Yoshida W, Uzuki M, Kurose A, Yoshida M, Nishida J, Shimamura T et al (2003) Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis. Hum Pathol 34:65–73CrossRefPubMed Yoshida W, Uzuki M, Kurose A, Yoshida M, Nishida J, Shimamura T et al (2003) Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis. Hum Pathol 34:65–73CrossRefPubMed
10.
go back to reference Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259CrossRefPubMed Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259CrossRefPubMed
11.
go back to reference Berger I, Weckauf H, Helmchen B, Ehemann V, Penzel R, Fink B et al (2005) Rheumatoid arthritis and pigmented villonodular synovitis: comparative analysis of cell polyploidy, cell cycle phases and expression of macrophage and fibroblast markers in proliferating synovial cells. Histopathology 46:490–497CrossRefPubMed Berger I, Weckauf H, Helmchen B, Ehemann V, Penzel R, Fink B et al (2005) Rheumatoid arthritis and pigmented villonodular synovitis: comparative analysis of cell polyploidy, cell cycle phases and expression of macrophage and fibroblast markers in proliferating synovial cells. Histopathology 46:490–497CrossRefPubMed
12.
go back to reference Yudoh K, Matsuno H, Nezuka T, Kimura T (1999) Different mechanisms of synovial hyperplasia in rheumatoid arthritis and pigmented villonodular synovitis: the role of telomerase activity in synovial proliferation. Arthritis Rheum 42:669–677CrossRefPubMed Yudoh K, Matsuno H, Nezuka T, Kimura T (1999) Different mechanisms of synovial hyperplasia in rheumatoid arthritis and pigmented villonodular synovitis: the role of telomerase activity in synovial proliferation. Arthritis Rheum 42:669–677CrossRefPubMed
13.
go back to reference Kroot EJ, Kraan MC, Smeets TJ, Maas M, Tak PP, Wouters JM (2005) Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis 64:497–499CrossRefPubMed Kroot EJ, Kraan MC, Smeets TJ, Maas M, Tak PP, Wouters JM (2005) Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis 64:497–499CrossRefPubMed
14.
go back to reference Fiocco U, Sfriso P, Oliviero F, Sovran F, Scagliori E, Pagnin E, Vezzù M, Cozzi L, Botsios C, Nardacchione N, Di Maggio A, Rubaltelli L, Giacometti C, Calabrese F, Todesco S (2006) Intra-articular etanercept treatment for severe diffuse pigmented villonodular knee synovitis. Reumatismo 58(4):268–274PubMed Fiocco U, Sfriso P, Oliviero F, Sovran F, Scagliori E, Pagnin E, Vezzù M, Cozzi L, Botsios C, Nardacchione N, Di Maggio A, Rubaltelli L, Giacometti C, Calabrese F, Todesco S (2006) Intra-articular etanercept treatment for severe diffuse pigmented villonodular knee synovitis. Reumatismo 58(4):268–274PubMed
Metadata
Title
Intraarticular adalimumab in a patient with pigmented villonodular synovitis
Author
Senol Kobak
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1185-z

Other articles of this Issue 2/2011

Rheumatology International 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.